AU2019239481B2 - Dihydrochromene derivative - Google Patents

Dihydrochromene derivative Download PDF

Info

Publication number
AU2019239481B2
AU2019239481B2 AU2019239481A AU2019239481A AU2019239481B2 AU 2019239481 B2 AU2019239481 B2 AU 2019239481B2 AU 2019239481 A AU2019239481 A AU 2019239481A AU 2019239481 A AU2019239481 A AU 2019239481A AU 2019239481 B2 AU2019239481 B2 AU 2019239481B2
Authority
AU
Australia
Prior art keywords
cancer
compound
anticancer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019239481A
Other languages
English (en)
Other versions
AU2019239481A1 (en
Inventor
Hitoshi Ban
Miki HASHIZUME
Seiji Kamioka
Yusuke SAWAYAMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of AU2019239481A1 publication Critical patent/AU2019239481A1/en
Assigned to Sumitomo Pharma Co., Ltd. reassignment Sumitomo Pharma Co., Ltd. Amend patent request/document other than specification (104) Assignors: SUMITOMO DAINIPPON PHARMA CO., LTD.
Application granted granted Critical
Publication of AU2019239481B2 publication Critical patent/AU2019239481B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AU2019239481A 2018-03-20 2019-03-19 Dihydrochromene derivative Active AU2019239481B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-052971 2018-03-20
JP2018052971 2018-03-20
PCT/JP2019/011439 WO2019181939A1 (ja) 2018-03-20 2019-03-19 ジヒドロクロメン誘導体

Publications (2)

Publication Number Publication Date
AU2019239481A1 AU2019239481A1 (en) 2020-09-10
AU2019239481B2 true AU2019239481B2 (en) 2022-11-24

Family

ID=67986459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019239481A Active AU2019239481B2 (en) 2018-03-20 2019-03-19 Dihydrochromene derivative

Country Status (21)

Country Link
US (3) US10807993B2 (https=)
EP (1) EP3770162B1 (https=)
JP (4) JP6733072B2 (https=)
KR (1) KR102799186B1 (https=)
CN (1) CN111886237B (https=)
AU (1) AU2019239481B2 (https=)
CA (1) CA3092255A1 (https=)
CY (1) CY1126034T1 (https=)
DK (1) DK3770162T3 (https=)
EA (1) EA202092206A1 (https=)
ES (1) ES2941771T3 (https=)
FI (1) FI3770162T3 (https=)
HU (1) HUE062256T2 (https=)
MX (1) MX2020009763A (https=)
MY (1) MY202583A (https=)
PH (1) PH12020551497A1 (https=)
PL (1) PL3770162T3 (https=)
PT (1) PT3770162T (https=)
SG (1) SG11202007979UA (https=)
TW (1) TWI899051B (https=)
WO (1) WO2019181939A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3770162T3 (pl) * 2018-03-20 2023-06-05 Sumitomo Pharma Co., Ltd. Pochodne dihydrochromenu
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2025100519A1 (ja) * 2023-11-09 2025-05-15 住友ファーマ株式会社 ジヒドロクロメン誘導体を含むがんの治療剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016208592A1 (ja) * 2015-06-22 2016-12-29 大日本住友製薬株式会社 二環性複素環アミド誘導体
WO2017146128A1 (ja) * 2016-02-26 2017-08-31 大日本住友製薬株式会社 イミダゾリルアミド誘導体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045707A1 (en) 1999-12-21 2001-06-28 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20090111805A1 (en) 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US20080255149A1 (en) * 2005-09-27 2008-10-16 Novartis Ag Carboxyamine Compounds and Methods of Use Thereof
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
CA2990583A1 (en) 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
TW201821105A (zh) * 2016-10-20 2018-06-16 美商弗瑪治療公司 使用hdac11抑制劑之方法
PL3770162T3 (pl) 2018-03-20 2023-06-05 Sumitomo Pharma Co., Ltd. Pochodne dihydrochromenu
JP2020019752A (ja) 2018-08-03 2020-02-06 大日本住友製薬株式会社 クロマン誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016208592A1 (ja) * 2015-06-22 2016-12-29 大日本住友製薬株式会社 二環性複素環アミド誘導体
WO2017146128A1 (ja) * 2016-02-26 2017-08-31 大日本住友製薬株式会社 イミダゾリルアミド誘導体

Also Published As

Publication number Publication date
KR102799186B1 (ko) 2025-04-23
CN111886237A (zh) 2020-11-03
US20230219970A1 (en) 2023-07-13
JP6733072B2 (ja) 2020-07-29
US20200216461A1 (en) 2020-07-09
MX2020009763A (es) 2020-10-08
JP2024123117A (ja) 2024-09-10
FI3770162T3 (fi) 2023-06-02
AU2019239481A1 (en) 2020-09-10
KR20200135401A (ko) 2020-12-02
CA3092255A1 (en) 2019-09-26
US20210002290A1 (en) 2021-01-07
EP3770162B1 (en) 2023-03-15
BR112020017481A8 (pt) 2022-12-06
CY1126034T1 (el) 2023-11-15
JPWO2019181939A1 (ja) 2020-06-18
SG11202007979UA (en) 2020-09-29
US10807993B2 (en) 2020-10-20
DK3770162T3 (da) 2023-04-24
EP3770162A4 (en) 2021-12-01
US11639357B2 (en) 2023-05-02
EP3770162A1 (en) 2021-01-27
PL3770162T3 (pl) 2023-06-05
HUE062256T2 (hu) 2023-10-28
MY202583A (en) 2024-05-09
US12398149B2 (en) 2025-08-26
CN111886237B (zh) 2025-02-07
JP7508620B2 (ja) 2024-07-01
ES2941771T3 (es) 2023-05-25
EA202092206A1 (ru) 2020-12-15
JP2023075288A (ja) 2023-05-30
NZ767234A (en) 2025-06-27
JP2020180140A (ja) 2020-11-05
BR112020017481A2 (pt) 2020-12-22
PT3770162T (pt) 2023-03-23
JP7247144B2 (ja) 2023-03-28
TWI899051B (zh) 2025-10-01
PH12020551497A1 (en) 2021-09-01
WO2019181939A1 (ja) 2019-09-26
TW201941774A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
AU2019348094B2 (en) Isoindoline compound, preparation method, pharmaceutical composition and use thereof
US12364702B2 (en) Highly active sting protein agonist compound
US12398149B2 (en) Dihydrochromene derivatives
CA3110436A1 (en) High activity sting protein agonist
CA3108449A1 (en) Optically active bridged piperidine derivative
US12410188B2 (en) Adenosine receptor antagonist
JP7287929B2 (ja) ジヒドロクロメン誘導体を含有する医薬
JP2020019752A (ja) クロマン誘導体
HK40043696A (en) Dihydrochromene derivatives
HK40043696B (en) Dihydrochromene derivatives
BR112020017481B1 (pt) Derivados de di-hidrocromeno, seu uso e composição farmacêutica
HK40048031A (en) Highly active sting protein agonist compound
HK40044966A (en) High activity sting protein agonist
EA041753B1 (ru) Производные дигидрохромена
HK40044966B (en) High activity sting protein agonist

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SUMITOMO PHARMA CO., LTD.

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA CO., LTD.

FGA Letters patent sealed or granted (standard patent)